These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 15901852)

  • 1. Characterization of a human carcinoma cell line selected for resistance to the farnesyl transferase inhibitor 4-(2-(4-(8-chloro-3,10-dibromo-6,11-dihydro-5H-benzo-(5,6)-cyclohepta(1,2-b)-pyridin-11(R)-yl)-1-piperidinyl)-2-oxo-ethyl)-1-piperidinecarboxamide (SCH66336).
    Bruzek LM; Poynter JN; Kaufmann SH; Adjei AA
    Mol Pharmacol; 2005 Aug; 68(2):477-86. PubMed ID: 15901852
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Farnesyl transferase inhibitor SCH66336 is cytostatic, pro-apoptotic and enhances chemosensitivity to cisplatin in melanoma cells.
    Smalley KS; Eisen TG
    Int J Cancer; 2003 Jun; 105(2):165-75. PubMed ID: 12673674
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The farnesyl transferase inhibitor (FTI) SCH66336 (lonafarnib) inhibits Rheb farnesylation and mTOR signaling. Role in FTI enhancement of taxane and tamoxifen anti-tumor activity.
    Basso AD; Mirza A; Liu G; Long BJ; Bishop WR; Kirschmeier P
    J Biol Chem; 2005 Sep; 280(35):31101-8. PubMed ID: 16006564
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Exploring the role of bromine at C(10) of (+)-4-[2-[4-(8-chloro-3,10-dibromo- 6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11(R)-yl)-1-piperidinyl]-2- oxoethyl]-1-piperidinecarboxamide (Sch-66336): the discovery of indolocycloheptapyridine inhibitors of farnesyl protein transferase.
    Taveras AG; Aki C; Chao J; Doll RJ; Lalwani T; Girijavallabhan V; Strickland CL; Windsor WT; Weber P; Hollinger F; Snow M; Patton R; Kirschmeier P; James L; Liu M; Nomeir A
    J Med Chem; 2002 Aug; 45(18):3854-64. PubMed ID: 12190309
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analogues of 1-(3,10-dibromo-8-chloro-6,11-dihydro-5H-benzo-[5,6]-cyclohepta [1,2-b]pyridin-11-yl)piperidine as inhibitors of farnesyl protein transferase.
    Afonso A; Weinstein J; Kelly J; Wolin R; Rosenblum SB; Connolly M; Guzi T; James L; Carr D; Patton R; Bishop WR; Kirshmeier P; Liu M; Heimark L; Chen KJ; Nomeir AA
    Bioorg Med Chem; 1999 Sep; 7(9):1845-55. PubMed ID: 10530932
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The farnesyltransferase inhibitor LB42708 suppresses vascular endothelial growth factor-induced angiogenesis by inhibiting ras-dependent mitogen-activated protein kinase and phosphatidylinositol 3-kinase/Akt signal pathways.
    Kim CK; Choi YK; Lee H; Ha KS; Won MH; Kwon YG; Kim YM
    Mol Pharmacol; 2010 Jul; 78(1):142-50. PubMed ID: 20406854
    [TBL] [Abstract][Full Text] [Related]  

  • 7. (+)-4-[2-[4-(8-Chloro-3,10-dibromo-6,11-dihydro-5H-benzo[5, 6]cyclohepta[1,2-b]- pyridin-11(R)-yl)-1-piperidinyl]-2-oxo-ethyl]-1-piperidinecarboxamid e (SCH-66336): a very potent farnesyl protein transferase inhibitor as a novel antitumor agent.
    Njoroge FG; Taveras AG; Kelly J; Remiszewski S; Mallams AK; Wolin R; Afonso A; Cooper AB; Rane DF; Liu YT; Wong J; Vibulbhan B; Pinto P; Deskus J; Alvarez CS; del Rosario J; Connolly M; Wang J; Desai J; Rossman RR; Bishop WR; Patton R; Wang L; Kirschmeier P; Ganguly AK
    J Med Chem; 1998 Nov; 41(24):4890-902. PubMed ID: 9822558
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Establishment and characterization of acquired resistance to the farnesyl protein transferase inhibitor R115777 in a human colon cancer cell line.
    Smith V; Rowlands MG; Barrie E; Workman P; Kelland LR
    Clin Cancer Res; 2002 Jun; 8(6):2002-9. PubMed ID: 12060646
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activity of the farnesyl protein transferase inhibitor SCH66336 against BCR/ABL-induced murine leukemia and primary cells from patients with chronic myeloid leukemia.
    Peters DG; Hoover RR; Gerlach MJ; Koh EY; Zhang H; Choe K; Kirschmeier P; Bishop WR; Daley GQ
    Blood; 2001 Mar; 97(5):1404-12. PubMed ID: 11222387
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The farnesyl protein transferase inhibitor SCH66336 is a potent inhibitor of MDR1 product P-glycoprotein.
    Wang E; Casciano CN; Clement RP; Johnson WW
    Cancer Res; 2001 Oct; 61(20):7525-9. PubMed ID: 11606389
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of potential markers of farnesyltransferase inhibition.
    Adjei AA; Davis JN; Erlichman C; Svingen PA; Kaufmann SH
    Clin Cancer Res; 2000 Jun; 6(6):2318-25. PubMed ID: 10873082
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of insulin-like growth factor binding protein-3 and farnesyltransferase inhibitor SCH66336 on Akt expression and apoptosis in non-small-cell lung cancer cells.
    Lee HY; Moon H; Chun KH; Chang YS; Hassan K; Ji L; Lotan R; Khuri FR; Hong WK
    J Natl Cancer Inst; 2004 Oct; 96(20):1536-48. PubMed ID: 15494604
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Farnesyltransferase inhibitor SCH66336 induces rapid phosphorylation of eukaryotic translation elongation factor 2 in head and neck squamous cell carcinoma cells.
    Ren H; Tai SK; Khuri F; Chu Z; Mao L
    Cancer Res; 2005 Jul; 65(13):5841-7. PubMed ID: 15994961
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of the farnesyl protein transferase inhibitor SCH66336 on isoprenylation and signalling by the prostacyclin receptor.
    O'Meara SJ; Kinsella BT
    Biochem J; 2005 Feb; 386(Pt 1):177-89. PubMed ID: 15469414
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Insulin-like growth factor-I receptor signaling pathway induces resistance to the apoptotic activities of SCH66336 (lonafarnib) through Akt/mammalian target of rapamycin-mediated increases in survivin expression.
    Oh SH; Jin Q; Kim ES; Khuri FR; Lee HY
    Clin Cancer Res; 2008 Mar; 14(5):1581-9. PubMed ID: 18316583
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of cell growth in human glioblastoma cell lines by farnesyltransferase inhibitor SCH66336.
    Glass TL; Liu TJ; Yung WK
    Neuro Oncol; 2000 Jul; 2(3):151-8. PubMed ID: 11302335
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Implication of protein kinase B/Akt and Bcl-2/Bcl-XL suppression by the farnesyl transferase inhibitor SCH66336 in apoptosis induction in squamous carcinoma cells.
    Chun KH; Lee HY; Hassan K; Khuri F; Hong WK; Lotan R
    Cancer Res; 2003 Aug; 63(16):4796-800. PubMed ID: 12941797
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibitors of farnesyl protein transferase. 4-Amido, 4-carbamoyl, and 4-carboxamido derivatives of 1-(8-chloro-6,11-dihydro-5H-benzo[5,6]- cyclohepta[1,2-b]pyridin-11-yl)piperazine and 1-(3-bromo-8-chloro-6,11- dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl)piperazine.
    Mallams AK; Rossman RR; Doll RJ; Girijavallabhan VM; Ganguly AK; Petrin J; Wang L; Patton R; Bishop WR; Carr DM; Kirschmeier P; Catino JJ; Bryant MS; Chen KJ; Korfmacher WA; Nardo C; Wang S; Nomeir AA; Lin CC; Li Z; Chen J; Lee S; Dell J; Lipari P; Liu M
    J Med Chem; 1998 Mar; 41(6):877-93. PubMed ID: 9526562
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The farnesyl protein transferase inhibitor SCH66336 synergizes with taxanes in vitro and enhances their antitumor activity in vivo.
    Shi B; Yaremko B; Hajian G; Terracina G; Bishop WR; Liu M; Nielsen LL
    Cancer Chemother Pharmacol; 2000; 46(5):387-93. PubMed ID: 11127943
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Isotype-specific Ras.GTP-levels predict the efficacy of farnesyl transferase inhibitors against human astrocytomas regardless of Ras mutational status.
    Feldkamp MM; Lau N; Roncari L; Guha A
    Cancer Res; 2001 Jun; 61(11):4425-31. PubMed ID: 11389071
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.